At a glance
- Originator Bristol-Myers Squibb
- Class Anti-inflammatories; Antiasthmatics; Antipsoriatics; Antirheumatics; Small molecules
- Mechanism of Action 5-lipoxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma; Psoriasis; Rheumatoid arthritis; Ulcerative colitis
Most Recent Events
- 29 May 1995 No-Development-Reported for Psoriasis in USA (unspecified route)
- 29 May 1995 No-Development-Reported for Rheumatoid arthritis in USA (unspecified route)
- 29 May 1995 No-Development-Reported for Ulcerative colitis in USA (unspecified route)